<DOC>
	<DOC>NCT00340834</DOC>
	<brief_summary>This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon Î²-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.</brief_summary>
	<brief_title>Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male and female patients between ages 1855 with a diagnosis of multiple sclerosis (MS) Patients with a relapsingremitting disease course Patients with Expanded Disability Status Scale (EDSS) score of 05.5 Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc Pregnant or nursing women Patients who cannot tolerate treatment with an interferon Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FTY720</keyword>
	<keyword>Interferon</keyword>
	<keyword>RRMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Efficacy</keyword>
</DOC>